Matt Kapusta, uniQure CEO

UniQure trum­pets mid-stage da­ta for Hunt­ing­ton's dis­ease gene ther­a­py

UniQure on Tues­day re­leased new two-year da­ta on its Hunt­ing­ton’s dis­ease gene ther­a­py called AMT-130, send­ing its stock $QURE up by …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.